In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
We evaluated a novel truncated hygromycin A analog in which the furanose ring was replaced with a 2-fluoro-2-cyclopropylethyl substituent for its activity against multidrug resistant gram-positive bacteria and compared its activity to the activities of linezolid, quinupristin-dalfopristin, and vancomycin. CE-156811 demonstrated robust in vitro activity against gram-positive bacteria that was comparable to that of linezolid.
Stone
Gregory G
GG
Pfizer Global Research & Development, Groton/New London Laboratories, Pfizer Inc., Groton, Connecticut 06340, USA. gregory.stone@astrazeneca.com
Girard
Dennis
D
Finegan
Steve
S
Duignan
Joan
J
Schafer
John
J
Maloney
Meghan
M
Zaniewski
Richard P
RP
Brickner
Steven J
SJ
Wade
Sarah K
SK
Le
Phuong T
PT
Huband
Michael D
MD
D000081:Acetamides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology*; D002934:Cinnamates / Q000737:chemistry / Q000494:pharmacology*; D004149:Dioxoles / Q000737:chemistry / Q000494:pharmacology*; D024901:Drug Resistance, Multiple, Bacterial; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000302:isolation & purification; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D006921:Hygromycin B / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D066298:In Vitro Techniques; D000069349:Linezolid; D008826:Microbial Sensitivity Tests; D015394:Molecular Structure; D023303:Oxazolidinones / Q000494:pharmacology
D000081:Acetamides; D000900:Anti-Bacterial Agents; C531326:CE 156811; D002934:Cinnamates; D004149:Dioxoles; D023303:Oxazolidinones; D006921:Hygromycin B; C026273:hygromycin A; D000069349:Linezolid